You don’t really address the dosing controversy on vaccine efficacy, except mentioning that you think it’s dumb to worry about, but there is something potentially concerning there. There’s some evidence that the dosing interval is causing some differences between the vaccine efficacies reported in Israel and the UK. This discussion full of immunology science words I don’t understand says there is a measurable difference in response to delta for short vs long doses.
Overall, I’m not sure what to make of this—even if 3-week intervals is generating strong levels of neutralizing antibodies and won’t become highly infectious or severely ill, it seems important to know if 2 Pfizer gives ~65% or ~90% protection. Unfortunately, I don’t think we’ll see studies on this for a while, so if anyone has better interpretations of this data it would be useful.
You don’t really address the dosing controversy on vaccine efficacy, except mentioning that you think it’s dumb to worry about, but there is something potentially concerning there. There’s some evidence that the dosing interval is causing some differences between the vaccine efficacies reported in Israel and the UK. This discussion full of immunology science words I don’t understand says there is a measurable difference in response to delta for short vs long doses.
The results from Israel, which used a 3-week dose interval, look bad, and contrast with the UKs results, which were (mostly) on 8-12 week intervals. But there are apparently sampling biases which mean the Israel data might not be fully reliable. See also here.
Overall, I’m not sure what to make of this—even if 3-week intervals is generating strong levels of neutralizing antibodies and won’t become highly infectious or severely ill, it seems important to know if 2 Pfizer gives ~65% or ~90% protection. Unfortunately, I don’t think we’ll see studies on this for a while, so if anyone has better interpretations of this data it would be useful.